Filing Flows › Arcus Biosciences (RCUS) › Q1 2026
Arcus Biosciences (RCUS) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 5, 2026
Arcus Biosciences (RCUS) reported revenue of $17.0M for the first quarter 2026 (Q1 2026), -39% from a year earlier and -48% from the quarter before. Operating margin was -788.2%, net loss $128M (752.9% of revenue).
Arcus Biosciences, Q1 2026: revenue $17.0M (-39% year over year), operating margin -788.2%, net loss $128M, operating cash flow −$138M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.0M | -48% | -39% |
| Operating profit | −$134M | — | — |
| Net earnings | −$128M | — | — |
| Operating cash flow | −$138M | — | — |
What changed
Revenue was $17.0M in Q1 2026, down 39% year over year and down 48% from the previous quarter. License and development services was the largest line at 71% of revenue. License and development services lost $8.0M year over year (down 40%), 73% of the total change.
Operating costs exceeded revenue by $134.0M, an operating margin of -788.2%. Total costs grew 1% against a revenue fall of 39%. The quarter ended with a net loss of $128.0M, wider than the previous quarter's $106.0M loss.
Operating cash flow was −$138.0M. Non-cash charges added back $2.0M of depreciation and amortization and $19.0M of share-based compensation. Working capital and other items used $31.0M.
Questions
What was Arcus Biosciences' revenue in the first quarter 2026?
Arcus Biosciences (RCUS) reported revenue of $17.0M for the first quarter 2026 (Q1 2026), -39% from a year earlier and -48% from the quarter before.
Was Arcus Biosciences profitable in the first quarter 2026?
Operating loss was $134M (-788.2% of revenue) and net loss $128M.
Source: Arcus Biosciences 10-Q on SEC EDGAR.